The Use of Controlled Human Infection Models to Identify Correlates of Protection for Invasive Vaccines

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 11

PMID 39257585

Authors

Naina McCann

Margarete Paganotti Vicentine

Young Chan Kim

Andrew J Pollard

Affiliations

Soon will be listed here.

Abstract

Controlled human infection model (CHIM) studies, which involve deliberate exposure of healthy human volunteers to an infectious agent, are recognised as important tools to advance vaccine development. These studies not only facilitate estimates of vaccine efficacy, but also offer an experimental approach to study disease pathogenesis and profile vaccine immunogenicity in a controlled environment, allowing correlation with clinical outcomes. Consequently, the data from CHIMs can be used to identify immunological correlates of protection (CoP), which can help accelerate vaccine development. In the case of invasive infections, vaccination offers a potential instrument to prevent disease. Invasive disease, caused by the enteric fever pathogens serovar Typhi ( Typhi) and Paratyphi A, B and C, and nontyphoidal (iNTS), remains a significant cause of mortality and morbidity in low- and middle-income countries, resulting in over 200,000 deaths and the loss of 15 million DALYs annually. CHIM studies have contributed to the understanding of . Typhi infection and provided invaluable insight into the development of vaccines and CoP following vaccination against Typhi. However, CoP are less well understood for . Paratyphi A and iNTS. This brief review focuses on the contribution of vaccine-CHIM trials to our understanding of the immune mechanisms associated with protection following vaccines against invasive pathogens, particularly in relation to CoP.

References

Clarkson K, Frenck Jr R, Dickey M, Suvarnapunya A, Chandrasekaran L, Weerts H . Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. mSphere. 2020; 5(5). PMC: 7568644. DOI: 10.1128/mSphere.00988-19. View

Anttila M, Eskola J, Ahman H, Kayhty H . Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis. 1998; 177(6):1614-21. DOI: 10.1086/515298. View

Kantele A, Pakkanen S, Karttunen R, Kantele J . Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial. PLoS One. 2013; 8(4):e60583. PMC: 3620468. DOI: 10.1371/journal.pone.0060583. View

Hornick R, WOODWARD T . Appraisal of typhoid vaccine in experimentally infected human subjects. Trans Am Clin Climatol Assoc. 1967; 78:70-8. PMC: 2441150. View

Hornick R, GREISMAN S, WOODWARD T, DuPont H, Dawkins A, Snyder M . Typhoid fever: pathogenesis and immunologic control. N Engl J Med. 1970; 283(13):686-91. DOI: 10.1056/NEJM197009242831306. View

Smith C, Smith E, Rydlova A, Varro R, Hinton J, Gordon M . Protocol for the challenge non-typhoidal (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK. BMJ Open. 2024; 14(1):e076477. PMC: 10806722. DOI: 10.1136/bmjopen-2023-076477. View

Jin C, Gibani M, Moore M, Juel H, Jones E, Meiring J . Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017; 390(10111):2472-2480. PMC: 5720597. DOI: 10.1016/S0140-6736(17)32149-9. View

Schlesinger Y, Granoff D . Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA. 1992; 267(11):1489-94. View

Lundin B, Johansson C, Svennerholm A . Oral immunization with a Salmonella enterica serovar typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect Immun. 2002; 70(10):5622-7. PMC: 128315. DOI: 10.1128/IAI.70.10.5622-5627.2002. View

10.

Dahora L, Verheul M, Williams K, Jin C, Stockdale L, Cavet G . Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. Sci Immunol. 2021; 6(64):eabj1181. PMC: 9960181. DOI: 10.1126/sciimmunol.abj1181. View

11.

Davies L, Cizmeci D, Guo W, Luedemann C, Alexander-Parrish R, Grant L . Polysaccharide and conjugate vaccines to generate distinct humoral responses. Sci Transl Med. 2022; 14(656):eabm4065. PMC: 9885968. DOI: 10.1126/scitranslmed.abm4065. View

12.

Levine M, Ferreccio C, Black R, Tacket C, Germanier R . Progress in vaccines against typhoid fever. Rev Infect Dis. 1989; 11 Suppl 3:S552-67. DOI: 10.1093/clinids/11.supplement_3.s552. View

13.

Siber G, Schur P, Aisenberg A, Weitzman S, Schiffman G . Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med. 1980; 303(4):178-82. DOI: 10.1056/NEJM198007243030402. View

14.

Wahid R, Kotloff K, Levine M, Sztein M . Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902. Clin Immunol. 2019; 201:61-69. PMC: 6959129. DOI: 10.1016/j.clim.2019.03.003. View

15.

Hornick R, GREISMAN S, WOODWARD T, DuPont H, Dawkins A, Snyder M . Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med. 1970; 283(14):739-46. DOI: 10.1056/NEJM197010012831406. View

16.

McCann N, Emary K, Singh N, McLean F, Camara S, Jones E . Accelerating clinical development of a live attenuated vaccine against Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Paratyphi A infection in.... BMJ Open. 2023; 13(5):e068966. PMC: 10230971. DOI: 10.1136/bmjopen-2022-068966. View

17.

Ouedraogo A, Diarra A, Nebie I, Barry N, Kabore J, Tiono A . Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. J Pediatric Infect Dis Soc. 2023; 12(9):513-518. PMC: 10533206. DOI: 10.1093/jpids/piad058. View

18.

Juel H, Thomaides-Brears H, Darton T, Jones C, Jones E, Shrestha S . Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model. Front Immunol. 2018; 8:1916. PMC: 5776093. DOI: 10.3389/fimmu.2017.01916. View

19.

Zhu H, Chelysheva I, Cross D, Blackwell L, Jin C, Gibani M . Molecular correlates of vaccine-induced protection against typhoid fever. J Clin Invest. 2023; 133(16). PMC: 10425215. DOI: 10.1172/JCI169676. View

20.

Cardenas L, Clements J . Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev. 1992; 5(3):328-42. PMC: 358247. DOI: 10.1128/CMR.5.3.328. View